HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) for HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.)
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Foreign entity interest: Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) is a US domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENTON J FISK | — |
| ELI KOGAN | — |
| BETH RADA | — |
Health Issues HCR
Issues pertaining to drug pricing and reimbursement, transparency and patient access. HR 2163/S 464 "Safe Step Act," all provisions. Issues pertaining to CMS Rule CMS-1751-P, all provisions relating to telehealth flexibilities and social determinants of health. Issues pertaining to Social Determinants of Health (SDOH), including SDOH Caucus Request for Information. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Food and Drug Administration Proposed Rule, Docket No. FDA-2019-N-5711, Importation of Prescription Drugs, all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. Issues pertaining to CMS Rule CMS-5528-ANPRM relating to Medicare Program, "International Pricing Index Model for Medicare Part B Drugs," all provisions. Issues pertaining to CMS-55238-IFC relating to Medicare Program "Most Favored Nations Model," all provisions. HR 1425 Patient Protection and Affordable Care Enhancement Act, Title III, Lowering Prices through Fair Drug Price Negotiations, all provisions. Issues pertaining to Centers for Medicare & Medicaid Services (CMS) Proposed Rule "Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Part Liability (TPL) Requirements [Docket No. CMS 2020-0072], all provisions. S909 "Prescription Drug Price Relief Act," all provisions. HR 3684 "Infrastructure Investment and Jobs Act," all provisions. HR 5376 "To Provide for Reconciliation Pursuant to Title II of S. Con. Res. 14," all provisions relating to drug pricing and tax provisions. HR 5260 "Reduced Costs and Continued Cures Act," all provisions.
Foreign entity interest: Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) is a US domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JORDAN CHAPMAN | — |
| BRENTON J FISK | — |
| ELI KOGAN | — |
| BETH RADA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.